Amicus Therapeutics (NASDAQ:FOLD) Given "Sell (E+)" Rating at Weiss Ratings

Key Points

• Amicus Therapeutics has received a "Sell (E+)" rating reiterated by Weiss Ratings, while other analysts have varied opinions, with some raising their ratings to "Buy" or "Strong Buy."
• The stock has experienced a slight increase of 1.2% and currently trades at $8.26, with an average price target of $15.78.
• Institutional investors are actively adjusting their stakes, with significant increases in holdings reported by several firms during the second quarter.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report)'s stock had its "sell (e+)" rating reiterated by equities research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

A number of other analysts also recently issued reports on FOLD. Wall Street Zen raised shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, September 20th. Zacks Research raised shares of Amicus Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Monday. Needham & Company LLC raised Amicus Therapeutics from a "hold" rating to a "buy" rating and set a $14.00 target price on the stock in a report on Thursday, September 18th. Finally, Morgan Stanley raised Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $15.78.

Amicus Therapeutics Stock Up 1.2%

Shares of NASDAQ FOLD traded up $0.10 during trading on Wednesday, reaching $8.26. The company had a trading volume of 3,764,370 shares, compared to its average volume of 4,089,135. Amicus Therapeutics has a 12-month low of $5.51 and a 12-month high of $12.65. The stock has a market cap of $2.55 billion, a PE ratio of -68.83 and a beta of 0.56. The business's 50-day moving average is $7.62 and its 200 day moving average is $6.90. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92.

Institutional Trading of Amicus Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Park National Corp OH bought a new stake in Amicus Therapeutics during the 3rd quarter valued at approximately $129,000. Osaic Holdings Inc. grew its holdings in Amicus Therapeutics by 450.1% during the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 3,358 shares in the last quarter. Cim Investment Management Inc. increased its stake in Amicus Therapeutics by 100.7% in the 2nd quarter. Cim Investment Management Inc. now owns 67,113 shares of the biopharmaceutical company's stock worth $385,000 after acquiring an additional 33,681 shares during the last quarter. Headlands Technologies LLC increased its stake in Amicus Therapeutics by 184.7% in the 2nd quarter. Headlands Technologies LLC now owns 159,522 shares of the biopharmaceutical company's stock worth $914,000 after acquiring an additional 103,492 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co increased its stake in Amicus Therapeutics by 2.8% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 83,764 shares of the biopharmaceutical company's stock worth $480,000 after acquiring an additional 2,263 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.